Platinum Investment Management Ltd. Has $2.03 Million Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Platinum Investment Management Ltd. raised its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 30.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,900 shares of the company's stock after purchasing an additional 17,670 shares during the quarter. Platinum Investment Management Ltd. owned approximately 0.13% of Structure Therapeutics worth $2,031,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares during the period. Assetmark Inc. grew its position in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Structure Therapeutics during the fourth quarter worth approximately $40,000. Finally, Jones Financial Companies Lllp lifted its holdings in Structure Therapeutics by 29.8% during the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock worth $115,000 after purchasing an additional 971 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities reiterated a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price on the stock. Finally, William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR traded down $0.90 during trading hours on Friday, hitting $20.97. 413,318 shares of the stock were exchanged, compared to its average volume of 834,316. The company's fifty day simple moving average is $24.80 and its two-hundred day simple moving average is $31.79. The company has a market cap of $1.20 billion, a PE ratio of -28.34 and a beta of -2.37. Structure Therapeutics Inc. has a 1-year low of $19.39 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. As a group, sell-side analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.